Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its acquisition of Ambry Genetics ...

We recently published a list of Top 10 AI Stocks Trending On Wall Street. In this article, we are going to take a look at ...

TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech ...

Ambry Genetics drives innovation in diagnostics by launching cutting-edge genetic tests and technologies. Its broad collaborations, novel research projects, and networks for data sharing ...

Myriad and its partners in the suit says that even though the patents on the natural genes are invalidated, Gene by Gene and Ambry Genetics are still in violation of 10 patents on the BRCA gene ...

In Q3 2024, Tempus announced its intent to acquire Ambry Genetics in a deal valued at 15x EBITDA at $600mm, $375mm of which through cash and the remaining $225mm in equity. Ambry will expand ...

Together, these studies represent a major step forward in variant classification, providing essential data that helps clinicians better assess cancer risks tied to genetic mutations. Ambry ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its acquisition of Ambry Genetics, a ...

Financing was provided by Ares Management Credit funds. Ambry Genetics will continue operations as a wholly-owned subsidiary of Tempus under its current leadership team. Tempus is a technology ...